ASTRAZENECA PHARMA IND LT Latest Share Price (ASTRAZEN)
TODAY IN ONE LINE
ASTRAZEN is little changed at ₹6944.00 on average volume — a quiet consolidation day, hovering dangerously near its 52-week low.
With a market cap of ₹17,287.5 Cr., it trades at a P/E of 101.61. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
ASTRAZENECA PHARMA IND LT flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●High Capital EfficiencyROCE of 44.9% indicating pricing power
- ●Strong Return on EquityHealthy ROE of 21.5%
- ●High Promoter HoldingPromoters hold 75.0% skin-in-the-game
- ●Virtually Debt-FreeVery low Debt-to-Equity of 0.00x
- ●Positive Free Cash FlowFCF has been positive for 3 consecutive years
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
- ●Earnings DeclineEPS (TTM) has contracted by 23.0% YoY
- ●Sales ContractionQuarterly sales dropped 70.0% YoY
Latest ASTRAZENECA PHARMA IND LT News
What changed recently?
Recent events, corporate actions, and announcements.
ASTRAZENECA PHARMA IND LT valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for ASTRAZENECA PHARMA IND LT, framed against the sector median so the premium or discount is obvious at a glance.
ASTRAZENECA PHARMA IND LT trades at a P/E of 101.61× and P/B of 19.75×.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
ASTRAZENECA PHARMA IND LT technical analysis: indicators, pivots and CPR.
Latest RSI, MACD and moving-average signals plus the latest pivot and Central Pivot Range levels for ASTRAZENECA PHARMA IND LT — derived from the latest tape, not yesterday's close.
ASTRAZENECA PHARMA IND LT last traded at ₹6,944 with an intraday range of ₹6,900–₹7,062 — latest indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Last: ₹6944.00| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 7361.33 | +417.33 | +6.01% |
| R3 | 7199.33 | +255.33 | +3.68% |
| R2 | 7130.67 | +186.67 | +2.69% |
| R1 | 7037.33 | +93.33 | +1.34% |
| PIVOT | 6968.67 | 24.67 | 0.36% |
| CURRENT | 6944.00 | — | — |
| S1 | 6875.33 | -68.67 | -0.99% |
| S2 | 6806.67 | -137.33 | -1.98% |
| S3 | 6713.33 | -230.67 | -3.32% |
| S4 | 6551.33 | -392.67 | -5.65% |
ASTRAZEN is trading Below CPR, indicating Bearishness
CPR is Average
Day's range: ₹6905.5–₹6999
Trading Inside opening range
ASTRAZENECA PHARMA IND LT financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for ASTRAZENECA PHARMA IND LT — consolidated or standalone — with margins, YoY growth and key ratios inline.
ASTRAZENECA PHARMA IND LT reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹17,287.5 Cr. and reported EPS of ₹15.17.
ASTRAZENECA PHARMA IND LT segment analysis : revenue and profit mix.
Disclosed business segments at ASTRAZENECA PHARMA IND LT with their share of revenue and profit, switchable between consolidated and standalone reporting.
ASTRAZENECA PHARMA IND LT discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for ASTRAZENECA PHARMA IND LT.
Our AI distills the core fundamental drivers supporting ASTRAZENECA PHARMA IND LT, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
ASTRAZENECA PHARMA IND LT's investment case rests on 10 positive markers and 10 flagged concerns drawn from the latest reported filings.
What you're getting.
High ROE 21.49% and ROCE 46.62% demonstrate superior capital efficiency.
TTM revenue growth 20.40% outpaces pharmaceutical sector average growth.
Debt-free balance sheet with D/E ratio 0.0000 provides financial flexibility.
75% promoter holding signals strong management alignment and confidence.
Operating margin 11.28% supports healthy profitability in competitive market.
Key Risks.
Latest quarterly EPS declined 23.0% YoY despite revenue expansion.
Premium P/E valuation 114.17x far exceeds peer median ~45x, correction risk.
Negative free cash flow ₹-660.2 Cr in FY26 signals liquidity deterioration.
Low dividend yield 0.52% may deter income-focused investors.
Net profit margin 8.24% compressed versus historical levels, profitability concern.
Flip Conditions.
Valuation risk. a P/E above 132 would leave less room for earnings disappointment.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Return-quality risk. ROE below 16% would indicate weaker capital compounding.
Income thesis breaks if the dividend is cut or yield falls below 0.26%.
ASTRAZENECA PHARMA IND LT peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — ASTRAZENECA PHARMA IND LT is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
ASTRAZENECA PHARMA IND LT chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for ASTRAZENECA PHARMA IND LT — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
ASTRAZENECA PHARMA IND LT delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for ASTRAZENECA PHARMA IND LT over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in ASTRAZENECA PHARMA IND LT stood at 46.5% of traded volume, against a 20-day average of 57.0%.
ASTRAZENECA PHARMA IND LT announcements: results, concalls, ratings, M&A.
Filings ASTRAZENECA PHARMA IND LT sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
ASTRAZENECA PHARMA IND LT files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 145 documents below.
General Updates
AstraZeneca Pharma India Limited has informed the Exchange about General Updates
Action(s) taken or orders passed
AstraZeneca Pharma India Limited has informed the Exchange about Action(s) taken or orders passed
General Updates
AstraZeneca Pharma India Limited has informed the Exchange about General Updates
Analysts/Institutional Investor Meet/Con. Call Updates
AstraZeneca Pharma India Limited has informed the Exchange about Schedule of meet
Analysts/Institutional Investor Meet/Con. Call Updates
AstraZeneca Pharma India Limited has informed the Exchange about Schedule of meet
Investor decks & rating reports.
ASTRAZENECA PHARMA IND LT dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue ASTRAZENECA PHARMA IND LT has declared, sequenced by announce and record date.
ASTRAZENECA PHARMA IND LT corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About ASTRAZENECA PHARMA IND LT: business, sector, key facts.
What ASTRAZENECA PHARMA IND LT does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
ASTRAZENECA PHARMA IND LT operates in the Pharmaceuticals industry under the Healthcare sector, listed as NSE: ASTRAZEN, BSE: 506820.
AstraZeneca Pharma India Limited is a prominent biopharmaceutical company operating in India and globally. Its core business revolves around the manufacturing, distribution, and marketing of a diverse portfolio of pharmaceutical products. This encompasses a wide range of therapeutic areas, showcasing the company's significant presence in the global healthcare market.
A major portion of AstraZeneca Pharma India's business focuses on cardiovascular, renal, and metabolic diseases. Key products in this segment include CRESTOR, Forxiga, BRILINTA, Xigduo, and Seloken XL, all of which target specific needs within these therapeutic areas. The company's commitment to addressing these prevalent health concerns is a key aspect of its business strategy.
Oncology represents another significant pillar of AstraZeneca Pharma India's operations. The company manufactures and sells a variety of oncology medicines under well-known brand names such as TAGRISSO, CALQUENCE, Lynparza, ENHERTU, IMFINZI, and Zoladex. These medications target different types of cancers and contribute significantly to the company's revenue and its standing within the oncology treatment landscape.
Beyond cardiovascular and oncology, AstraZeneca Pharma India also caters to the rare diseases market with its Koselugo brand. The company's involvement in this area demonstrates a commitment to providing treatments for less common but equally significant health conditions. Further diversifying its portfolio, AstraZeneca Pharma India offers respiratory medicines such as Symbicort and Fasenra, addressing another significant area of healthcare needs.
In addition to its core product lines, AstraZeneca Pharma India also provides clinical trial services. This aspect of the business underscores the company's commitment to research and development, allowing them to contribute not just through marketed products but also through participation in the advancement of medical knowledge and treatment options. The company's offerings extend to diabetes and immunology diseases, further demonstrating the breadth of its therapeutic reach.
Established in 1979 and headquartered in Bengaluru, India, AstraZeneca Pharma India Limited is a subsidiary of AstraZeneca Pharmaceuticals AB. This connection to a larger global entity provides access to resources, expertise, and market reach, contributing to its success in the competitive pharmaceutical industry.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- AAREY DRUGS & PHARM (AAREYDRUGS) Share PricePeer
- AARTI DRUGS (AARTIDRUGS) Share PricePeer
- AARTI PHARMALABS (AARTIPHARM) Share PricePeer
- AJANTA PHARMA (AJANTPHARM) Share PricePeer
- AKUMS DRUGS AND PHARMA L (AKUMS) Share PricePeer
- Stocks near 52-week low (reversal watch)Screener
- Reversal Hunter strategy playbookStrategy
- Other overvalued NSE stocksScreener
- Top quality scorecard stocksScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about ASTRAZENECA PHARMA IND LT (ASTRAZEN).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of ASTRAZENECA PHARMA IND LT (ASTRAZEN)?
The current share price of ASTRAZENECA PHARMA IND LT (ASTRAZEN) is ₹6,944.00. Today, the stock has gained by ₹3.50 (0.05%), trading in a range of ₹6,900.00 to ₹7,062.00. The stock opened at ₹6,999.00 with a trading volume of 6,489 shares.
02Is ASTRAZENECA PHARMA IND LT stock a good investment for long-term?
ASTRAZENECA PHARMA IND LT can be considered for long-term investment based on several factors. The company has a market capitalization of ₹17,287.5 Cr., P/E ratio of 101.61, ROE of 21.49%, and ROCE of 44.9%. The dividend yield stands at 0.52%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of ASTRAZENECA PHARMA IND LT stock?
The 52-week high price of ASTRAZENECA PHARMA IND LT (ASTRAZEN) is ₹9,849.50, while the 52-week low is ₹6,835.00. Currently trading at ₹6,944.00, the stock is 1.59% above its 52-week low and 29.5% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy ASTRAZENECA PHARMA IND LT stock at the current price?
Whether to buy ASTRAZENECA PHARMA IND LT stock at ₹6,944.00 depends on multiple factors. The stock is currently trading with a P/E ratio of 101.61 and P/B ratio of 19.75. Today's performance shows a gain of 0.05%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of ASTRAZENECA PHARMA IND LT and when is the next dividend?
ASTRAZENECA PHARMA IND LT offers a dividend yield of 0.52%, which means for every ₹100 invested at the current price of ₹6,944.00, you can expect to receive approximately ₹0.52 annually as dividends. The face value of the stock is ₹2.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of ASTRAZENECA PHARMA IND LT?
ASTRAZENECA PHARMA IND LT's key financial metrics include: P/E Ratio: 101.61, P/B Ratio: 19.75, ROE: 21.49%, ROCE: 44.9%, Dividend Yield: 0.52%, EPS: ₹15.17, Book Value: ₹349.12, and Debt-to-Equity: 0. The company's market cap stands at ₹17,287.5 Cr.. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is ASTRAZENECA PHARMA IND LT stock performing today in the market?
ASTRAZENECA PHARMA IND LT stock opened at ₹6,999.00 and is currently trading at ₹6,944.00, showing a gain of ₹3.50 (0.05%). The intraday high is ₹7,062.00 and low is ₹6,900.00. The trading volume stands at 6,489 shares, indicating moderate market participation today.
08What is the P/E ratio of ASTRAZENECA PHARMA IND LT and what does it indicate?
ASTRAZENECA PHARMA IND LT has a Price-to-Earnings (P/E) ratio of 101.61, which means investors are willing to pay 101.61 for every ₹1 of earnings. With an EPS of ₹15.17, this P/E ratio suggests the stock may be trading at a premium, possibly due to high growth expectations. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about ASTRAZENECA PHARMA IND LT (ASTRAZEN) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.